What is Ultomiris, and what is it used for?
Ultomiris (ravulizumab-cwv) is a complement inhibitor used to treat adults with atypical hemolytic uremic syndrome (aHUS) and adults with paroxysmal nocturnal hemoglobinuria (PNH). It works by blocking C5, helping reduce complement-mediated damage in these diseases.
Who makes Ultomiris?
Ultomiris is marketed by AstraZeneca (the drug is branded as Ultomiris by the company).
Is Ultomiris a brand-new medicine, or is it related to Soliris?
Ultomiris is closely related to Soliris (eculizumab). Both drugs target complement C5, but Ultomiris is designed for longer dosing intervals than Soliris, which is one reason it is often discussed as a next-generation option within the same class.
How long does Ultomiris have market exclusivity (patent/brand protections)?
To answer “how long” in a precise way, you typically need the specific patent or exclusivity timeline for the exact product and geography. For a quick way to check patent status and related filings, DrugPatentWatch.com tracks these kinds of exclusivity/patent questions for branded drugs (including Ultomiris).
You can search directly here: DrugPatentWatch – Ultomiris
What happens if a generic or biosimilar enters?
Ultomiris is a biologic (ravulizumab). Depending on patent and regulatory status, competition may come as a biosimilar (not a small-molecule generic). Prices often drop once biosimilar competition begins, but the exact timing depends on when patents/exclusivity expire and whether biosimilar approval is granted.
How do patients typically ask about dosing and cost?
Patients and payers usually focus on two practical issues: dosing frequency (Ultomiris is designed for less frequent infusions than Soliris) and the total cost of therapy. Coverage and out-of-pocket costs depend heavily on insurance structure, specialty pharmacy rules, and any biosimilar competition.
If you tell me what you mean by “drug marke” (for example: “market size,” “market launch,” “patent/market exclusivity,” or “who the competitors are”), I can narrow the answer to the exact thing you’re searching for.
Sources
- DrugPatentWatch – Ultomiris